Utlizing the RA signature to predict response to TNFi

This study involves bulk RNA-seq analyses of blood cells from patients with rheumatoid arthritis who have had an inadequate response to methotrexate, collected before and 12 weeks after effective treatment with either etanercept or adalimumab. Peripheral blood mononuclear cells were stimulated with anti-CD3 for 24 hours and sorted into CD4+, CD19+, and CD4-CD19- (DN) populations for bulk RNA-seq.

• Type: Full Transcriptome Sequencing
• Archiver: The database of Genotypes and Phenotypes (dbGaP)